已收盤 11-20 16:00:00 美东时间
-0.620
-5.87%
Summit Therapeutics reported that the FDA issued a Complete Response Letter for its ivonescimab BLA in EGFR-mutated NSCLC, citing lack of statistically significant overall survival benefit despite a progression free survival advantage in the HARMONi Phase III trial. The rejection directly affects Summit Therapeutics’ only commercial-stage path for ivonescimab in its territories. It also increases pressure on the broader late stage trial program,
11-21 10:11
药企Insmed周升逾16%,赛诺菲酝酿重磅收购;泰森食品升逾10%,公司连续15年提高年度股息;Anthropic上市首周升逾7%>>
11-21 10:09
Summit Therapeutics (SMMT) is back in focus after the FDA issued a Complete Response Letter for ivonescimab in lung cancer, questioning overall survival evidence and the treatment’s benefit risk profile. The regulatory setback has hit Summit Therapeutics hard, with the 7-day share price return down about 30% and the 30-day share price return down roughly 34%. The 1-year total shareholder return is lower by about 36%, but the 3-year total sharehol
11-20 08:18
今日重点评级关注:HC Wainwright & Co.:维持Cerenome"买入"评级,目标价从1美元升至7美元;HC Wainwright & Co.:维持Greenwich LifeSciences"买入"评级,目标价从69美元升至70美元
11-19 19:40
Summit Therapeutics ( ($SMMT) ) just unveiled an update. On November 18, 2026, ...
11-18 21:49
Bernstein analyst Jeffrey Walch downgrades Summit Therapeutics (NASDAQ:SMMT) from Market Perform to Underperform and lowers the price target from $11.9 to $8.3.
11-18 20:57
11月18日,SUMMIT THERAPEUTIC(SMMT)收跌9.73%,报10.67美元,成交额1.42亿美元,市值85.33亿美元。 行情数据 • 开盘...
11-18 05:56
今日重点评级关注:康托·菲茨杰拉德:维持Lexeo Therapeutics"超配"评级,目标价从23美元升至37美元;摩根士丹利:维持Sana Biotechnology"超配"评级,目标价从12美元升至13美元
11-17 17:31
NEW YORK, Nov. 16, 2026 /PRNewswire/ -- Biotech Today News Commentary - Clinical and regulatory news moved several drug developers on a down day for the broader market. The S&P 500 fell 1.92...
11-17 07:34
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 来源:雷递 雷递网 雷建平 11月16日 港股企业康方生物...
11-16 22:36